GoodRx (Nasdaq: GDRX) announced it is working with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy in ...

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS ...

Neffy, an intranasal formulation of epinephrine, is now available for emergency treatment of type I allergic reactions.

Last week the FDA approved Neffy, an epinephrine nasal spray, for use in emergency allergic reactions for kids and adults. Retired allergist at the Northwest Asthma & Allergy Center Paul Williams ...

Whether it’s allergies, a sinus infection or runny nose, many people turn to nasal sprays for quick relief. Now, there’s ...

ARS Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) for a1 mg dose of nasal spray neffy, to treat ...

The submission of the neffy 1 mg sNDA follows the FDA approval of neffy (2 mg) on August 9, 2024, for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 kg ...

ARS Pharmaceuticals' neffy, a needle-free nasal spray for Type I allergic reactions, received early FDA approval, driving a 120% YTD share price increase. Neffy addresses a significant unmet need ...

Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Rubin is a pediatrician specializing in allergy and immunology.

Credit: ARS Pharmaceuticals. Neffy is indicated for adult and pediatric patients weighing at least 30kg. It is recommended that patients be prescribed and have immediate access to 2 neffy nasal ...